The Bull Case For AbbVie (ABBV) Could Change Following EU Approval Of Rinvoq For Vitiligo Simply Wall St 12:12 Wed, 29 Jul
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata AbbVie (Press Release) 08:00 Wed, 29 Jul
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo AbbVie (Press Release) 08:00 Wed, 29 Jul
